Kusuyama T, Okuyama Y, Fujita M, Taguchi T
Dept. of Surgery, Research Institute for Microbial Diseases, Osaka University.
Gan To Kagaku Ryoho. 1990 Feb;17(2):259-67.
We studied fundamentally subrenal capsule assay, using human tumor specimens (breast, gastric and colon cancers) serially transplanted in nude mice. When cancer anticancer agents such as mitomycin C (MMC) and 5-fluorouracil (5-FU) were injected into immunocompetent mice treated with various dosages of cyclosporin A (CsA) after tumor implantation, optimal schedule of each drug was examined on the points of effects and toxicity against host mice. The following results were obtained. Control groups were set up as immunocompetent mice which treated daily with 60 mg/kg CsA from day 1 after tumor implantation. Optimal treatment schedule was judged as MMC 3 mg/kg i.v. injection on day 1 following by daily 60 mg/kg CsA treatment, and 5-FU was injected 25 mg/kg subcutaneous injection every day from day 1 without CsA treatment, each schedule showed an appropriate anti-tumor activity profiles against implanted tumor xenografts, and had less toxicity to the hosts.
我们使用在裸鼠中连续移植的人类肿瘤标本（乳腺癌、胃癌和结肠癌），对肾包膜下测定法进行了基础研究。当在肿瘤植入后用不同剂量的环孢素A（CsA）处理的免疫活性小鼠中注射丝裂霉素C（MMC）和5-氟尿嘧啶（5-FU）等癌症抗癌药物时，从对宿主小鼠的疗效和毒性方面检查了每种药物的最佳给药方案。获得了以下结果。对照组设置为从肿瘤植入后第1天起每天用60mg/kg CsA处理的免疫活性小鼠。最佳治疗方案判定为第1天静脉注射MMC 3mg/kg，随后每天用60mg/kg CsA处理，5-FU从第1天起每天皮下注射25mg/kg且不进行CsA处理，每个方案对植入的肿瘤异种移植物均显示出适当的抗肿瘤活性，且对宿主的毒性较小。
